小细胞食管癌的综合治疗疗效分析

Efficacy analysis of comprehensive treatment in small cell esophageal carcinoma following resection

目的总结小细胞食管癌综合治疗的效果。方法回顾性收集2000年3月至2011年3月北京大学肿瘤医院胸外一科单一手术组收治的食管癌患者的临床资料，内容涉及肿瘤特征、分期、治疗方案、疗效、短期预后及长期生存。结果共计手术治疗食管癌患者546例，其中小细胞食管癌患者15例（2．7％）。15例小细胞食管癌患者除1例接受单纯手术治疗以外，其余14例均接受了以手术为主的综合治疗，其中接受术前化疗4例，术后化疗lO例；另有4例患者接受了术后放疗。1例术后3个月内死亡，未纳入生存分析，其余14例患者的中位生存期为14．3个月．明显劣于同期治疗的其他组织类型食管癌患者的42．2个月（P〈0．05）。结论小细胞食管癌发病率较低．疗效较差。

Objective To summarize the surgical outcome of patients with small cell esophageal carcinoma （SCEC）. Methods Clinical data of patients with esophageal carcinoma were retrospectively collected from March 2000 to March 2011 at the Thoracic Surgery Department of the Peking University Cancer Hospital. Data included tumor characteristics, staging, treatment, response, short-term outcome, and long-term survival. Results A total of 546 patients with esophageal carcinoma were identified, among whom there were 15 patients with SCEC （2.7%）. Fourteen cases received multimodality treatment based on operation and one underwent operation alone. Four patients had preoperative chemotherapy and 10 had postoperative chemotherapy. Four patients had postoperative radiation. After excluding one case of postoperative death within 3 months, the median overall survival was 14.3 months （range, 4 to 99 months）, signifiantly worse than those with non-SCEC （42.2 months, P〈0.05）. Conclusion SCEC is rare and the outcomes are poor. It should be considered as a systematic disease.